OTC Medicines

(WASHINGTON, D.C.) – The Consumer Healthcare Products Association (CHPA) today announced the appointment of M. Scott Furness, Ph.D., to serve as its new Senior Vice President of Regulatory & Scientific Affairs. Dr. Furness comes to CHPA from the U.S. Food and Drug Administration (FDA) where he spent more than 25 years in various leadership roles, most recently as Director of the Division of Product Quality Assessment XVIII at the Center for Drug Evaluation and Research’s (CDER) Office of Pharmaceutical Quality (OPQ), overseeing the scientific review and quality evaluation of the active pharmaceutical ingredient (API) section of regulatory applications and providing strategic guidance on pharmaceutical quality issues. Dr. Furness takes the role previously held by Mike Bailey and officially began his work at CHPA on May 6, 2025. He will serve as a member of CHPA’s Senior Management Team and report to President and CEO Scott Melville.

(WASHINGTON, D.C.) — The Consumer Healthcare Products Association (CHPA) released the following statement today after submitting comments to the U.S. Department of Commerce’s Bureau of Industry and Security (BIS) regarding its Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients:

(WASHINGTON, DC) – The Consumer Healthcare Products Association’s (CHPA) Health In Hand Foundation today announced its call for nominations for the 2025 U.S. Self-Care Marketing Awards. Winners will be announced at the 10th annual Health In Hand Foundation Gala on Nov. 12 at The Bellevue Hotel in Philadelphia.

(WASHINGTON, D.C.) – The Consumer Healthcare Products Association (CHPA) released the following statement today in response to U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr. and Food and Drug Administration (FDA) Commissioner Dr. Marty Makary announcing plans to phase out petroleum-based synthetic dyes from the national food supply and replace them with natural ingredients:

(WASHINGTON, D.C.) — Consumer Healthcare Products Association (CHPA) President & CEO Scott Melville today released the following statement in response to the White House’s executive order, “Lowering Drug Prices by Once Again Putting Americans First,” issued this week.

(WASHINGTON, D.C.) — The Consumer Healthcare Products Association (CHPA) today responded to an announcement from the Department of Commerce this week regarding the initiation of a Section 232 investigation into the national security implications of pharmaceutical imports, including finished drug products, active pharmaceutical ingredients (APIs), and other critical materials:

(WASHINGTON, D.C.) — The Consumer Healthcare Products Association (CHPA) today released the following statement echoing concerns U.S. Reps. Bob Latta (OH-05), Dan Crenshaw (TX-02), and Mariannette Miller-Meeks (IA-01) raised to the U.S. Food and Drug Administration (FDA), urging the Agency to strike the simultaneous marketing portion of the preamble that is tied to the final rule for Nonprescription Drug Product With an Additional Condition for Nonprescription Use (ACNU):

(Washington, D.C.) – The Consumer Healthcare Products Association (CHPA) released the below statement today following a House Energy and Commerce Subcommittee on Health hearing featuring testimony from Kevin Menzel, President of Focus Consumer Healthcare, a CHPA member company, and other industry experts, to discuss the importance of reauthorizing the OTC Monograph Drug User Fee Program (OMUFA).